Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib plus pembrolizumab in previously treated advanced lung adenocarcinoma
2016-003609-32Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bemcentinib, pembrolizumab in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by BerGenBio ASA. Started Mar 2017; status: completed.
02
Drugs
bemcentinibpembrolizumab
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2016-003609-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003609-32.